AU2016219173B2 - Blockers of the growth hormone receptor in disease prevention and treatment - Google Patents

Blockers of the growth hormone receptor in disease prevention and treatment Download PDF

Info

Publication number
AU2016219173B2
AU2016219173B2 AU2016219173A AU2016219173A AU2016219173B2 AU 2016219173 B2 AU2016219173 B2 AU 2016219173B2 AU 2016219173 A AU2016219173 A AU 2016219173A AU 2016219173 A AU2016219173 A AU 2016219173A AU 2016219173 B2 AU2016219173 B2 AU 2016219173B2
Authority
AU
Australia
Prior art keywords
ghr
compound
igf
stat5
halogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2016219173A
Other languages
English (en)
Other versions
AU2016219173A1 (en
Inventor
Priya BALASUBRAMANIAN
Valter D. Longo
Nouri Neamati
Min Wei
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Southern California USC
Original Assignee
University of Southern California USC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Southern California USC filed Critical University of Southern California USC
Publication of AU2016219173A1 publication Critical patent/AU2016219173A1/en
Application granted granted Critical
Publication of AU2016219173B2 publication Critical patent/AU2016219173B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
AU2016219173A 2015-02-12 2016-02-12 Blockers of the growth hormone receptor in disease prevention and treatment Ceased AU2016219173B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562115356P 2015-02-12 2015-02-12
US62/115,356 2015-02-12
PCT/US2016/017717 WO2016130901A2 (en) 2015-02-12 2016-02-12 Blockers of the growth hormone receptor in disease prevention and treatment

Publications (2)

Publication Number Publication Date
AU2016219173A1 AU2016219173A1 (en) 2017-08-17
AU2016219173B2 true AU2016219173B2 (en) 2020-02-20

Family

ID=56615057

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016219173A Ceased AU2016219173B2 (en) 2015-02-12 2016-02-12 Blockers of the growth hormone receptor in disease prevention and treatment

Country Status (14)

Country Link
US (2) US10246446B2 (enExample)
EP (1) EP3256465B1 (enExample)
JP (2) JP6930916B2 (enExample)
KR (1) KR20180016333A (enExample)
CN (1) CN107438605B (enExample)
AU (1) AU2016219173B2 (enExample)
BR (1) BR112017017182A2 (enExample)
CA (1) CA2976219C (enExample)
ES (1) ES2871551T3 (enExample)
IL (1) IL253943A0 (enExample)
MX (1) MX383010B (enExample)
NZ (1) NZ734252A (enExample)
RU (1) RU2726254C2 (enExample)
WO (1) WO2016130901A2 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11284640B2 (en) 2017-02-14 2022-03-29 University Of Southern California Fasting mimicking diet
CN112153974A (zh) 2018-03-15 2020-12-29 南加利福尼亚大学 禁食模仿膳食(fmd)而非仅饮水禁食促进炎症和ibd病理学的逆转

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9701010D0 (sv) * 1997-03-19 1997-03-19 Pharmacia & Upjohn Ab Antibody
JPWO2002096892A1 (ja) 2001-05-31 2004-09-09 小野薬品工業株式会社 オキサジアゾール誘導体化合物およびその化合物を有効成分とする薬剤
WO2006001770A1 (en) * 2004-06-28 2006-01-05 Biovitrum Ab Method for identifying modulators of cytokine class i receptor
RU2415134C9 (ru) * 2005-08-15 2011-05-27 Этерна Центарис ГмбХ Способ лечения или профилактики физиологических и/или патофизиологических состояний, опосредуемых рецепторами, стимулирующими секрецию гормона роста, триазолы и фармацевтическая композиция на их основе
US8519137B2 (en) 2007-10-11 2013-08-27 Vertex Pharmaceuticals Incorporated Heteroaryl amides useful as inhibitors of voltage-gated sodium channels
AU2008352540B2 (en) * 2008-03-14 2012-06-28 Biocon Limited A monoclonal antibody and a method thereof
JP5731501B2 (ja) * 2009-07-28 2015-06-10 コーニンクレッカ フィリップス エヌ ヴェ ロック構造を有するハウジング
RU2014123030A (ru) * 2011-12-22 2016-02-20 Ринат Ньюросайенс Корп. Антагонистические антитела против человеческого рецептора гормона роста и способы их применения
WO2013123511A1 (en) * 2012-02-16 2013-08-22 New York University Control of hypoxia-inducible gene expression with oligooxopiperazine nonpeptidic helix mimetics
WO2013192165A2 (en) 2012-06-20 2013-12-27 University Of Kansas Compounds and methods for activating the apoptotic arm of the unfolded protein response
KR20150124962A (ko) 2013-02-12 2015-11-06 유니버시티 오브 써던 캘리포니아 화학 독성 및 연령 관련 질병으로부터 보호하기 위한 방법 및 규정식

Non-Patent Citations (16)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACT, (2004-09-24), Database accession no. 750624-95-4, URL: STN *
CHEMICAL ABSTRACT, (2004-09-27), Database accession no. 752215-38-6, URL: STN *
CHEMICAL ABSTRACT, (2006-01-18), Database accession no. 872119-65-8, URL: STN *
CHEMICAL ABSTRACT, (2006-01-20), Database accession no. 872319-25-0, URL: STN *
CHEMICAL ABSTRACT, (2007-03-15), Database accession no. 926515-91-5, URL: STN *
CHEMICAL ABSTRACT, (2007-10-09), Database accession no. 949831-32-7, URL: STN *
CHEMICAL ABSTRACT, (2007-10-09), Database accession no. 949847-41-0, URL: STN *
CHEMICAL ABSTRACT, (2008-04-02), Database accession no. 1011657-63-8, URL: STN *
CHEMICAL ABSTRACT, (2008-04-14), Database accession no. 1014381-09-9, URL: STN *
CHEMICAL ABSTRACT, (2008-12-26), Database accession no. 1090351-93-1, URL: STN *
CHEMICAL ABSTRACT, (2009-07-29), Database accession no. 1169951-41-0, URL: STN *
CHEMICAL ABSTRACT, (2009-09-04), Database accession no. 1180203-07-9, URL: STN *
CHEMICAL ABSTRACT, (2009-09-04), Database accession no. 1180307-90-7, URL: STN *
CHEMICAL ABSTRACT, (2010-01-24), Database accession no. 1203233-04-8, URL: STN *
CHEMICAL ABSTRACT, (2011-04-15), Database accession no. 1280496-33-4, URL: STN *
Chemical Abstract, (2011-08-28), Database accession no. 1324757-41-6, URL: STN *

Also Published As

Publication number Publication date
US20190276445A1 (en) 2019-09-12
EP3256465A2 (en) 2017-12-20
CN107438605A (zh) 2017-12-05
MX2017010306A (es) 2018-03-15
US20170342063A1 (en) 2017-11-30
BR112017017182A2 (pt) 2018-04-03
EP3256465B1 (en) 2021-04-07
CN107438605B (zh) 2021-03-19
RU2726254C2 (ru) 2020-07-10
AU2016219173A1 (en) 2017-08-17
RU2017129335A3 (enExample) 2019-08-07
CA2976219A1 (en) 2016-08-18
JP2018506534A (ja) 2018-03-08
NZ734252A (en) 2020-06-26
JP2021075553A (ja) 2021-05-20
EP3256465A4 (en) 2018-10-31
CA2976219C (en) 2021-05-04
WO2016130901A2 (en) 2016-08-18
WO2016130901A3 (en) 2016-10-20
ES2871551T3 (es) 2021-10-29
RU2017129335A (ru) 2019-03-12
KR20180016333A (ko) 2018-02-14
JP6930916B2 (ja) 2021-09-01
US10246446B2 (en) 2019-04-02
IL253943A0 (en) 2017-10-31
MX383010B (es) 2025-03-13

Similar Documents

Publication Publication Date Title
US20230404949A1 (en) Method of treating or preventing neurodegeneration
CN110234647B (zh) 用于调节免疫应答的氧杂双环庚烷
EP3723781B1 (en) Peptides and other agents for treating pain and increasing pain sensitivity
JP2024154382A (ja) Ａｂｃｂ５のリガンドおよび基質
US9724337B2 (en) AG-205 for the treatment of breast cancer
US20190276445A1 (en) Blockers of the growth hormone receptor in disease prevention and treatment
US20240408071A1 (en) Novel combination of serotonin receptor (5-htr2b) antagonist and an immunomodulator and chemotherapeutic drugs for inhibition of cancer
US11919854B2 (en) P2RX7 modulators in therapy
EP3250218B1 (en) Naktide peptide for treating obesity
US20240141436A1 (en) Compounds, Compositions and Methods of Treatment Thereof
US20100330098A1 (en) Methods to regulate glucose metabolism
WO2015073813A2 (en) Compositions and methods for the treatment of diseases involving hippo pathway
EP1745799A2 (en) Compositions and methods of treating tumors
HK40037093A (en) Peptides and other agents for treating pain and increasing pain sensitivity
HK40037093B (en) Peptides and other agents for treating pain and increasing pain sensitivity
EP3458048A1 (en) Combination therapies using indazolylbenzamide derivatives for the treatment of cancer
HK1100070A (en) Compositions and methods of treating tumors

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired